Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound glycyrrhizin for prevention or mitigation of gemcitabine-associated rash and liver function abnormalities
ChiCTR-IIR-17012919Phase 2Not yet recruiting
- Sponsor
- Department of Abdominal Oncology, West China Hospital
- Start
- Feb 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of glycyrrhizinate in toxicoderma (cADR) (2 arms), sponsored by Department of Abdominal Oncology, West China Hospital. Primary endpoints: Size of skin rash and Liver function indexes. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
glycyrrhizinate
03
Conditions
toxicoderma (cADR)
Beyond the preview
Go deeper on ChiCTR-IIR-17012919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012919.